Press Releases Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Real-time Estimate Cboe Europe Other stock markets 04:50:10 16/05/2024 pm IST			5-day change	1st Jan Change
6.905 ^SEK	+2.75%		+9.25%	+22.76%

03/05	Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
22/02	Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bulletin from Egetis Therapeutics’ Annual General Meeting 2024	06/05	AQ
Egetis Therapeutics Q1 2024 - EU launch closing in	06/05	AQ
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)	24/04	AQ
Egetis Therapeutics' : 2023 Annual Report published	15/04	PU
Egetis Therapeutics’ 2023 Annual Report published	15/04	AQ
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)	29/03	PU
Egetis Therapeutics - Continued progress in Q4	23/02	AQ
Egetis Therapeutics : – Corporate Presentation December 2023	27/12	PU
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance	22/12	AQ
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today	19/12	AQ
Egetis’ Investor Day on December 19: Agenda and Registration Details	14/12	AQ
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA	13/12	AQ
Save the Date: Egetis to host Investor Day on December 19, 2023	01/12	AQ
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan	10/11	AQ
Egetis Therapeutics - All eyes on eventful 2024	09/11	AQ
Egetis Therapeutics has resolved on directed issues of warrants and a convertible bond within the framework of the drawdown of Tranche A of the previously communicated debt financing	07/11	AQ
Egetis recruits Desiree Luthman as Vice President Global Regulatory Affairs	07/11	AQ
Egetis’ Nomination Committee for the 2024 Annual General Meeting	01/11	AQ
Change in the number of shares and votes in Egetis Therapeutics	31/23/31	AQ
Egetis announces EMA validation of Marketing Authorisation Application for Emcitate for the treatment of MCT8 deficiency	27/23/27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Press Releases

Filters